Skip to main content
Premium Trial:

Request an Annual Quote

Gail Norris, Lisa Kuuttila, Michael Christman

Gail Norris has been named director of the University of Rochester’s Office of Technology Transfer, the school said last week.
Norris has been serving as interim director of the office since last year. Prior to this, she was employed as a lawyer in the University of Rochester’s Office of Counsel, where she specialized in technology transfer. Norris has also served as general counsel, US operations, for Celltech Pharmaceuticals; and was a partner in the law firm of Nixon Peabody. She holds a law degree from Albany Law School of Union University.

Michigan State University last week announced that Lisa Kuuttila has been named director of MSU Technologies, MSU’s recently formed technology transfer organization.
Kuuttila has been assistant vice president for technology commercialization at Purdue Research Foundation; director of technology commercialization at University of Georgia; and director of the Office of Technology Commercialization at the Center for Advanced Technology Development at Iowa State University. She holds a master’s degree in public administration from Iowa State University, and a BS in electrical engineering from the University of Michigan.

The Coriell Institute for Medical Research last week said that Michael Christman was appointed president and CEO, effective June 1, 2007.
Christman joins Coriell Institute from Boston University School of Medicine, where he was professor and founding chair of the department of genetics and genomics. He has also served as associate professor of microbiology at the University of Virginia, and assistant professor of radiation oncology at the University of California, San Francisco. He completed his postdoctoral work at the Massachusetts Institute of Technology, and holds a PhD in biochemistry from the University of California, Berkeley.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.